Multiple Sclerosis Severity: Genetic, Environmental, and Epigenetic Determinants of Disease Progression
Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system characterised by inflammation, demyelination, neurodegeneration, and progressive neurological disability. Although genome-wide association studies have identified 233 genetic loci associated with MS susceptibility, the determinants of disease severity remain far less well understood. The reviewed article emphasises that understanding why some patients accumulate disability rapidly while others remain relatively stable is now a central challenge in MS research, particularly because severity reflects not only disease onset but also long-term CNS resilience, repair capacity, and neurodegenerative burden.
The DYSF–ZNF638 Locus and CNS Resilience
A major focus of the article is the discovery of the rs10191329 variant in the DYSF–ZNF638 region, currently the only genome-wide significant locus reliably associated with MS severity. This variant has been linked to accelerated disability accumulation, including a reduction of approximately 3.7 years in the median time to requiring walking assistance. The biological relevance of this locus is notable: DYSF encodes DYSFerlin, a protein potentially involved in membrane maintenance in neurons and glia, while ZNF638 encodes a transcriptional regulator expressed in oligodendrocytes, cells essential for myelin formation and maintenance.
Why Genetic Studies of MS Severity Have Been Difficult
The limited success of GWAS in identifying severity-associated variants is not necessarily evidence that genetics is unimportant in MS progression. Instead, the article highlights several methodological obstacles, including insufficient sample sizes, inconsistent phenotyping, and reliance on measures such as the Multiple Sclerosis Severity Score, which depends on uncertain disease-onset dates. Disease heterogeneity further complicates discovery, because relapsing-remitting, secondary progressive, and primary progressive MS may involve partially distinct biological mechanisms. These issues reduce statistical power and can obscure subtype-specific genetic effects.
Environmental Risk Factors and the Problem of Causality
The review also examines non-genetic contributors to MS severity, including smoking, high body mass index, low vitamin D levels, lipid abnormalities, reduced physical activity, and educational attainment. Observational studies have associated several of these factors with worse disability outcomes, but such studies are vulnerable to confounding and reverse causation. For example, patients with more severe MS may exercise less and spend less time outdoors, which could secondarily influence weight and vitamin D status. This makes it difficult to determine whether the exposure drives progression or merely reflects it.
Mendelian Randomisation as a Tool for Causal Inference
Mendelian randomisation offers a more rigorous strategy for testing causal relationships by using genetic variants as proxies for lifelong exposure to a risk factor. According to the article, MR studies have supported causal links between higher genetically predicted BMI, heavier smoking, lower educational attainment, and worse MS severity. In contrast, MR analyses have not consistently supported causal roles for vitamin D levels, serum lipids, or age at menopause in MS severity. These discrepancies illustrate that environmental associations observed in clinical cohorts may not always represent direct causal mechanisms.
Epigenetics as a Bridge between Genes and Environment
A particularly important theme of the review is the emerging role of epigenetic regulation in MS progression. DNA methylation, histone modifications, and noncoding RNAs can alter gene expression without changing the DNA sequence, thereby providing a plausible biological interface between inherited risk, environmental exposures, and disease course. The article discusses evidence that methylation changes in immune cells, altered histone regulation in microglia and astrocytes, and dysregulated microRNAs may contribute to inflammation, impaired remyelination, neurodegeneration, and long-term disability accumulation.
Toward Integrated and Personalised MS Severity Research
The article concludes that future progress will require large, longitudinal, deeply phenotyped studies that integrate GWAS, Mendelian randomisation, epigenome-wide association studies, transcriptomics, proteomics, imaging, and functional validation. The DYSF–ZNF638 locus provides an important entry point into the biology of CNS resilience, but it is unlikely to explain MS severity alone. A more comprehensive framework must account for genetic architecture, environmental exposures, epigenetic plasticity, immune activity, and neurodegenerative mechanisms. Such integration may ultimately improve prognostic modelling, identify therapeutic targets, and support more personalised strategies to delay disability progression in MS.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Almramhi, M. Multiple sclerosis severity: integrative insights into genetic and nongenetic risk factors. Egypt J Neurol Psychiatry Neurosurg 62, 95 (2026). https://doi.org/10.1186/s41983-026-01164-7
